Disclosed is a localised surface plasmon resonance (LSPR) nanopillar assembly. The LSPR assembly is for use in sensing the presence of a biomarker when attached to a quantum dot. The LSPR assembly comprises a substrate and an array. The array comprises a LSPR nanopillar and a polymer spacer attached to the nanopillar. The LSPR assembly further comprises an antibody attached to the at least one polymer spacer. In the LSPR assembly, a combined height of the polymer spacer and antibody is selected by varying the number of monomer units of the polymer spacer, so that, when in use with the biomarker and the quantum dot, the quantum dot is at a predetermined distance from the nanopillar.

The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).

Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.

The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.

A method of measuring a concentration of an analyte is provided, including: reacting a test solution including an analyte with a nanoparticle solution including a plurality of nanoparticles and an optical waveguide element to form a sandwich-like structure; and measuring evanescent wave energy of the optical waveguide element absorbed and/or scattered by the plurality of nanoparticles after the plurality of nanoparticles forming the sandwich-like structure by using a photodetector to obtain a first signal, and calculating the concentration of the analyte based on the first signal. Wherein, a detection recognition element is conjugated on a surface of each of the plurality of nanoparticles, and a capture recognition element is conjugated on a waveguide surface of the optical waveguide element.

The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.

This disclosure describes portable bio-nano-chip assays, methods and compositions for diagnosing trauma at point-of-care using biological samples. The assays, methods and compositions provide in a more convenient, less expensive, and less time-consuming sampling and analysis.

An in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from the subject and the correlation of the determined level to a potential risk of sustaining an adverse event.

The present disclosure provides a rapid test for determining state of an infection (e.g., a coronavirus such as Covid-2019) in a subject. The test may include the steps of detecting of an antibody specific to the pathogen in a blood sample from the subject, and detecting and quantitating the level of at least one inflammatory biomarker in the same subject.

This disclosure describes portable bio-nano-chip assays, methods and compositions for diagnosing and assessing pathogen-mediated diseases or infections at point-of-care using biological samples. The assays, methods and compositions provide in a more convenient, less expensive, and less time-consuming sampling and analysis.